11 February 2014 - Drug maker Celgene Corporation said Tuesday that Health Canada has approved Pomalyst oral therapy (pomalidomide capsules) in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen. The company expects that Pomalyst will be commercially available in March 2014.

For more details, go to: http://www.rttnews.com/2267213/celgene-health-canada-approves-pomalyst-for-patients-with-multiple-myeloma.aspx?type=fdp